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Background
Acute psychotic illness, especially when associated with 
agitated or violent behavior, can require urgent pharma-
cological tranquillization or sedation. In many countries, 
benzodiazepines (either alone or in combination with 
antipsychotics) are often used in this situation (1).
Objectives
To examine whether benzodiazepines, alone or in com-
bination with other pharmacological agents, are an 
effective treatment for psychosis-induced aggression or 
agitation when compared with placebo, other pharmaco-
logical agents (alone or in combination) or non-pharma-
cological approaches.
Search Methods
We searched the Cochrane Schizophrenia Group’s regis-
ter (January 2012, August 20, 2015 and August 3, 2016), 
inspected reference lists of included and excluded studies, 
and contacted authors of relevant studies.
Selection Criteria
We included all randomized controlled trials (RCTs) 
comparing benzodiazepines alone or in combination 
(with antipsychotics), vs placebo or antipsychotics alone 
or in combination (with other antipsychotics, benzodiaz-
epines or antihistamines) for people who were aggressive 
or agitated due to psychosis.
Data Collection and Analysis
We reliably selected studies, quality assessed them, and 
extracted data. For binary outcomes, we calculated 
standard estimates of  risk ratio (RR) and their 95% CI 
using a ixed-effect model. For continuous outcomes, we 
calculated the mean difference (MD) between groups. 
If  there was heterogeneity, this was explored using a 
random-effects model. We assessed the risk of  bias and 
created a “Summary of  indings” table using GRADE 
(table 1).
Main Results
Twenty trials including 695 participants are included 
in this review. The quality of  evidence for the main 
outcomes was low or very low due to the very small 
sample sizes of  included studies and serious risk of 
bias (randomization, allocation concealment and 
blinding were not well conducted in the included tri-
als, and 6 out of  the 20 trials were supported by phar-
maceutical institutes). There was no clear effect for 
most outcomes.
Benzodiazepines Alone vs Placebo
One trial compared benzodiazepines alone (IM loraze-
pam) with placebo. There was no difference in the num-
ber sedated at 24 hours (very low quality of evidence). 
However, more people receiving placebo showed no 
improvement in global state in the medium term (1 to 
48 h) (n = 102, 1 RCT, RR 0.62, 95% CI 0.40 to 0.97, very 
low quality of evidence).
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Table 1. Summary of Findings: Benzodiazepines Compared to Antipsychotics for Psychosis-Induced Aggression or Agitation
Patient or population: people with psychosis-induced aggression or agitation
Settings: hospitals (United States, Canada, Israel, China, Australia)
Intervention: benzodiazepines
Comparison: antipsychotics
Outcomes Illustrative comparative risks  
(95% CI)
Relative effect  
(95% CI)
No of  
participants  
(studies)
Quality  
of the  
evidence 
(GRADE)
Comments
Assumed risk Corresponding risk
Antipsychotics Benzodiazepines
Tranquillisation or asleep: sedation - 
medium term vs haloperidol
Number of participants sedated Follow-up: 
mean 16 h
Low RR 1.13  
(0.83 to 1.54)
434 (8 studies) ๨๨๰๰ Lowa,b —
100 per 1000 113 per 1000  
(83 to 154)
Moderatee
227 per 1000 257 per 1000  
(189 to 350)
High
500 per 1000 565 per 1000  
(415 to 770)
Global state: no improvement -  
vs haloperidol - medium term
As deined in each study Follow-up: 24 h
Low RR 0.89  
(0.71 to 1.11)
188 (5 studies) ๨๨๰๰ Lowa,b —
77 per 1000 68 per 1000  
(55 to 85)
Moderatec
619 per 1000 551 per 1000  
(439 to 687)
High
933 per 1000 830 per 1000  
(662 to 1000)
Global state: no improvement -  
vs olanzapine - medium term
As deined in each study Follow-up: 24 h
192 per 1000 353 per 1000  
(203 to 610)
RR 1.84  
(1.06 to 3.18)
150 (1 study) ๨๰๰๰ Very 
lowa,b,g
—
Global state: need for additional medication - 
medium term Number of participants  
requiring additional medication  
Follow-up: 24 h
See comment See comment Not estimable 216 (2 studies) ๨๰๰๰ Very 
lowa,b,d
High levels of heterogeneity 
between included studies 
(χ2 = 16.41; I2 = 94%) − data not 
pooled.d
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Outcomes Illustrative comparative risks  
(95% CI)
Relative effect  
(95% CI)
No of  
participants  
(studies)
Quality  
of the  
evidence 
(GRADE)
Comments
Assumed risk Corresponding risk
Antipsychotics Benzodiazepines
Adverse effects/events: extrapyramidal 
symptoms - vs haloperidol - medium term
Number of instances of extrapyramidal 
symptoms Follow-up: 21 h
Low RR 0.13  
(0.04 to 0.41)
233 (6 studies) ๨๨๰๰ Lowa,b —
0 per 1000 0 per 1000  
(0 to 0)
Moderatef
186 per 1000 24 per 1000  
(7 to 76)
High
500 per 1000 65 per 1000  
(20 to 205)
Satisfaction with treatment: from the 
perspective of consumer, family and 
informal care givers or professionals/carers 
at any point during the acute management 
stage
See comment See comment Not estimable 0 (0) See comment No study reported this outcome.
Economic outcomes: cost-effectiveness See comment See comment Not estimable 0 (0) See comment No study reported this outcome.
GRADE Working Group grades of evidence
High quality: we are very conident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately conident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially 
different.
Low quality: our conidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little conidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
Note: The basis for the “assumed risk” (eg, the median control group risk across studies) is provided in footnotes. The “corresponding risk” (and its 95% CI) is based on the 
assumed risk in the comparison group and the “relative effect” of the intervention (and its 95% CI). RR, risk ratio.
aRisk of bias: “serious”—most trials received funding from a pharmaceutical institute, and there was a potential risk of selection bias.
bImprecision: “serious”—CIs for the best estimate of effect included both “no effect” and appreciable beneit/harm.
cAssumed risk: calculated from the included studies—presented 3 risks based on the control group risks—“moderate” risk equates with that of the control group (61.9%).
dInconsistency: “serious”—one study indicated signiicant favor of antipsychotics, while the other study indicated favor for benzodiazepines (nonsigniicant).
eAssumed risk: calculated from the included studies—presented 3 risks based on the control group risks—“moderate” risk equates with that of the control group (22.7%).
fAssumed risk: calculated from the included studies—presented 3 risks based on the control group risks—“moderate” risk equates with that of the control group (18.6%).
gOnly one small study reporting data.
Table 1. Continued
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Benzodiazepines Alone vs Antipsychotics
Eleven trials compared benzodiazepines with antipsy-
chotics. Compared with haloperidol there was no differ-
ence for sedation at 16 hours (n = 434, 8 RCTs, RR 1.13, 
95% CI 0.83 to 1.54, low quality of evidence) or improve-
ment (global state) in the medium term (n = 188, 5 RCTs, 
RR 0.89, 95% CI 0.71 to 1.11, low quality of evidence).
In one small trial, fewer participants improved (global 
state) in the medium term when receiving lorazepam 
compared with olanzapine (n  =  150, 1 RCT, RR 1.84, 
95% CI 1.06 to 3.18, very low quality of evidence).
People receiving benzodiazepines were less likely to 
experience extrapyramidal effects (EPS) in the medium 
term compared to people receiving haloperidol (n = 233, 
6 RCTs, RR 0.13, 95% CI 0.04 to 0.41, low quality of 
evidence).
Benzodiazepines Alone vs Combined Antipsychotics/
Antihistamines
When benzodiazepines (lorazepam or midazolam) were 
compared with combined antipsychotics/antihistamines 
(haloperidol plus promethazine), there was a higher risk 
of no improvement (global state) for benzodiazepines 
alone in the medium term (n = 200, 1 RCT, RR 2.17, 95% 
CI 1.16 to 4.05, low quality of evidence). However, for 
sedation in the medium term, the results were unclear: 
compared with combined antipsychotics/antihistamines, 
lorazepam led to a lower risk of sedation (n  =  200, 1 
RCT, RR 0.91, 95% CI 0.84 to 0.98, low quality of evi-
dence); while, midazolam led to a higher risk of sedation 
(n = 200, 1 RCT, RR 1.13, 95% CI 1.04 to 1.23, low qual-
ity of evidence).
Other Combinations
Benzodiazepines (lorazepam or clonazepam) plus anti-
psychotics (haloperidol or risperidone) vs benzodiaz-
epines alone did not yield any clear differences for global 
state. When comparing combined benzodiazepines/anti-
psychotics (a haloperidol combination in all studies) with 
haloperidol alone, there was no difference in medium-
term improvement for global state (n = 185, 4 RCTs, RR 
1.17, 95% CI 0.93 to 1.46, low quality of evidence), but 
sedation was more likely in the short-term for people who 
received the combination therapy (n = 172, 3 RCTs, RR 
1.75, 95% CI 1.14 to 2.67, very low quality of evidence). 
Only one trial compared combined benzodiazepines/anti-
psychotics with antipsychotics; however, this study did 
not report our primary outcomes. One small trial com-
pared combined benzodiazepines/antipsychotics (mid-
azolam and haloperidol) with combined antihistamines/
antipsychotics (promethazine and haloperidol). The 
combined benzodiazepines/antipsychotics group had a 
higher risk of no improvement (global state) (n = 60, 1 
RCT, RR 25.00, 95% CI 1.55 to 403.99, very low quality 
of evidence) and higher levels of sedation in the medium 
term (n = 60, 1 RCT, RR 12.00, 95% CI 1.66 to 86.59, 
very low quality of evidence).
Authors’ Conclusions
The small amount of evidence is of poor quality. Most 
trials were too small to highlight differences. A  direct 
comparison of single agent benzodiazepines vs anti-
psychotics demonstrated a possible small advantage of 
antipsychotics. However, caution must be exercised as 
older antipsychotic agents also had a disadvantage in 
terms of side effects (EPS). Adding benzodiazepines to 
other drugs does not seem to confer clear advantage and 
has the potential for adding unnecessary adverse effects. 
It would appear that antihistamines would be a better 
choice of additive agent to antipsychotics than benzodi-
azepines; however, the quality of evidence was very low. 
Much more high-quality research is still needed in this 
area.
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